In this paper, we address the trajectory planning problem in uncertain nonconvex static and dynamic environments that contain obstacles with probabilistic location, size, geometry. To problem, provide a risk-bounded method looks for continuous-time trajectories guaranteed bounded risk over time horizon. Risk is defined as probability of collision obstacles. Existing approaches to problems eithe...

Many blind people require travel aids to navigate in unknown environments. However, the majority of the corresponding devices are not designed for people with walking disabilities. In this paper, we present a smart walker that does not only provide walking assistance but also enables blind users with mobility impairment to avoid obstacles. By leveraging existing robotics technologies, our syste...

This paper presents a new method for computing the connguration-space map of obstacles that is used in motion-planning algorithms. The method derives from the observation that, when the robot is a rigid object that can only translate, the connguration space is a convolution of the workspace and the robot. This convolution is computed with the use of the Fast Fourier Transform (FFT) algorithm. T...

in this paper i will review the possibility,meaning and importance of comparative studies.although there are some increasing activities in this field, there are some obstacles in this comparison. these difficulties arise from hermeneutical meanings of the problems and the cultural diversities and the different approaches in the same problems. these matters bring the suspicion of impossibility a...

Swarm intelligence was originally inspired in social behaviour in nature, also considering the evolving aspects, several variations in swarm intelligence’s techniques made it applicable to optimization problems. In this paper two case studies of static environment, composed with obstacles are presented and evaluated, a comparative study is evaluated between two techniques of swarm intelligence ...

Drug repositioning (DR) is the process of identifying new indications for existing drugs. DR usually focuses on drugs that have cleared phase-I safety trials but has yet to show efficacy for the intended indication. Therefore, DR can probably skip the preclinical and phase-I study, which can reduce the cost throughout drug development. However, the expensive phase-II/III trials are required to ...